Liver Cancer Trial, Recruiting NCT05629845 Sponsor: Chinese University of Hong Kong Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT05629845
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have been diagnosed with hepatocellular carcinoma (liver cancer) and have recently experienced bleeding from enlarged veins in the esophagus or stomach, where that bleeding was successfully treated within the past 4 weeks using standard procedures such as band ligation or glue injection
  • People who are able to give written consent to take part and follow the study procedures

Who may not be able to join:

  • People who are unable to give written consent to participate
  • People whose other health conditions make it unsafe for them to undergo an endoscopy (a camera procedure)
  • People with liver cancer whose gastrointestinal bleeding came from a source other than enlarged veins
  • People with severely abnormal blood clotting or very low platelet counts that have not improved after receiving blood products (confirm with trial site for specific thresholds)
  • People who are critically unwell due to a terminal illness with very limited life expectancy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Raymond S Tang, MD, Chinese University of Hong Kong

Phone: (852) 26370428

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 November 2022
Est. completion
31 December 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

90-day death adjusted cumulative incidence of variceal rebleeding after secondary prevention by EUS-guided therapy or conventional endoscopic therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov